# Medeligo

> AI-powered oncology literature and treatment information app. (iPhone/iPad app by LiveMed Media Ltd..)

- Source: https://appshunter.io/ios/app/medeligo/id1000247107 (this page in markdown: same URL + `.md`)
- Developer: [LiveMed Media Ltd.](https://appshunter.io/developer/979061491)
- Category: Medical
- Price: Free with in-app purchases
- Rating: 5.00/5 from 9 App Store ratings · 5 written reviews indexed
- Age rating: 17+
- Requires: iOS 14.0 · 4 MB
- Languages: American English
- Released: 2016-02-19
- Data updated: 2026-06-11
- Monetization: free with in-app purchases
- User reviews in markdown: https://appshunter.io/ios/app/medeligo/id1000247107/reviews.md

## What is Medeligo?

Medeligo® provides instant access to the latest oncology literature and information for treatment, procedure, testing, and management information across all oncology subspecialties.

FINGERTIP ACCESS TO THE LATEST ONCOLOGY INFORMATION

- AI-powered search engineered by technologists and medical librarians
- Effortless UI gets to answers in seconds
- Covers more than 2,000 solid tumors and cancers, including the WHO Classification of Tumours
- Real-time searches provide the latest information available
- Searches only the most trusted medical journals, databases, and information resources
- Primary source material: unfiltered, unbiased, uncurated

Benefits include:

- Find and read the latest oncology literature in seconds
- Watch relevant videos and browse images
- Prepare for patient rounds, consults, and surgeries
- Answer patient-specific questions quickly at tumor boards
- Share, print, or save articles

Limited introductory price of $49.99 (Reg. $149.99) for the All Access (1 year) subscription — includes a risk-free 3-month trial.

To learn more, please visit www.medeligo.com.

After the free trial period, your subscription will continue for $49.99/year, and your iTunes account will be charged. If you do not wish to continue your subscription after your free trial ends, turn off auto-renew in your Account Settings 24 hours before the end of your free trial.
Subscriptions will automatically renew when they expire unless you turn off auto-renew at least 24 hours before the end of your subscription period. Your account will be charged $49.99 for renewal within 24 hours before the end of your subscription period. You can manage your subscription and turn off auto-renew by going to your Account Settings.
Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable.

You can read more about our terms and conditions here:
Privacy policy: http://medeligo.com/privacy-policy/
Terms of service: http://medeligo.com/terms-of-service/

## Key features

- AI-powered search
- Real-time oncology information
- Covers 2,000+ cancer types
- Access to literature, videos, and images
- Trusted medical journal searches
- Save, share, and print articles

## Pricing and in-app purchases

Base price: Free.

**Subscriptions**

| Subscription | Price | Period |
| --- | --- | --- |
| All Access (1 year) | $24.99 | per year |


## Recent user reviews (5 of 5)

All indexed reviews: https://appshunter.io/ios/app/medeligo/id1000247107/reviews.md

### 5/5 — Highly Recommend

*2024-03-12, version 1.5.4*

Awesome APP, provides clinically relevant information at your fingertips.

### 5/5 — Highly recommend!

*2020-11-11, version 1.4.9*

So glad I found this app. How did I not know about it? It’s easy to use and provides fast access to information that I otherwise might not have time to find.

### 5/5 — Wonderful application

*2016-11-28, version 1.0.5*

Medeligo is an great application. It offers an easy to use interface to engage in an extensive search engine and database. The use for immediate access to specific question regarding specific pathologies makes this application particularly useful. I would recommend this product for anyone who engages in clinical or basic science oncology research.

### 5/5 — Pediatric Neurosurgery

*2016-11-28, version 1.0.5*

I have been using the app for about 6 months and have found it to be very useful. It makes valuable information on pediatric brain tumors easily available. I've also had the opportunity to share it with my residents who use it to read about upcoming cases or consults. I definitely recommend the app.

### 5/5 — Precise, reliable, essential!

*2016-11-22, version 1.0.5*

The Medeligo app is beyond anything I have used before. I used the app on the fly during my neurosurgical sub-internships nearly everyday. It’s a great way to look up information before cases and patient encounters and is an amazing resource for general study purposes. The app has become an essential for me, it’s truly helpful!

## Frequently asked questions about Medeligo

### What is Medeligo?

Medeligo provides instant access to the latest oncology literature and information for treatment, procedure, testing, and management across all oncology subspecialties. It uses AI-powered search to quickly find answers from trusted medical journals and databases.

### What kind of content does Medeligo offer?

Medeligo offers access to the latest oncology literature, including research articles, videos, and images. It covers over 2,000 solid tumors and cancers, referencing the WHO Classification of Tumours.

### How does Medeligo's search work?

Medeligo features an AI-powered search engine, engineered by technologists and medical librarians. This allows for effortless UI and quick retrieval of answers from the most trusted medical journals, databases, and information resources.

### What are the benefits of using Medeligo?

Benefits include finding and reading the latest oncology literature in seconds, preparing for patient rounds and consults, answering patient-specific questions quickly, and the ability to share, print, or save articles.

### What is the pricing for Medeligo?

Medeligo is available for free with an 'All Access' subscription for $49.99 per year, which includes a risk-free 3-month trial. The regular price is $149.99 per year.

### How do I manage my Medeligo subscription?

Subscriptions automatically renew unless auto-renew is turned off at least 24 hours before the end of the subscription period. You can manage your subscription and turn off auto-renew in your Account Settings.

### Does Medeligo have ads?

Yes, Medeligo contains advertisements. It is offered as a free app with an in-app purchase for an 'All Access' subscription.

### What devices is Medeligo compatible with?

Medeligo is compatible with iPhone and iPod devices. It is rated for ages 17+.

## Version history (last 5 releases)

### 1.5.4 — 2022-12-05

• Users can now delete their accounts.

### 1.5.3 — 2022-06-28

• View a list of relevant societies across each subspecialty.

### 1.5.0 — 2020-12-16

• Improved search yields more contemporaneous results when using "Recent Articles" category.

### 1.4.9 — 2020-07-23

• Updated to support Dark Mode and Dynamic Type.
• Performance enhancements and bug fixes.

### 1.4.7 — 2020-03-24

Performance enhancements and bug fixes

## Apps similar to Medeligo

| App | Rating | Price | Category |
| --- | --- | --- | --- |
| [Washington Manual of Oncology](https://appshunter.io/ios/app/washington-manual-of-oncology/id1242386143) | — | Free | Medical |
| [Neuro-oncology: WTD](https://appshunter.io/ios/app/neuro-oncology-wtd/id1502145529) | 5.0 (6) | Free | Medical |
| [Head & Neck Cancer Manager](https://appshunter.io/ios/app/head-and-neck-cancer-manager/id1364066880) | 5.0 (2) | Free | Medical |
| [high5 breast cancer](https://appshunter.io/ios/app/high5-breast-cancer/id6472849782) | — | Free | Medical |
| [The NeuroICU Board Review](https://appshunter.io/ios/app/the-neuroicu-board-review/id1437856729) | 5.0 (2) | $99.99 | Medical |
| [Pocket Oncology](https://appshunter.io/ios/app/pocket-oncology/id6748145936) | 5.0 (2) | Free | Medical |

---

*Data collected daily from the US App Store and indexed by [AppsHunter](https://appshunter.io/). User reviews are verbatim App Store reviews. Ratings, prices and chart positions refresh continuously; this snapshot is from 2026-06-11.*
